Insider Transaction Report

Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc., reported a transaction on December 22, 2025. He acquired 13,000 shares of Common Stock at a price of $2.48 per share, increasing his post-transaction holdings to 36,000 shares. Additionally, Mr. Hohl exercised a stock option for 13,000 shares of Common Stock, with a conversion or exercise price of $2.48. This resulted in him holding 92,056 shares in total following the option exercise. All shares subject to the option were fully vested.